Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
How this was made
The 30-second read
Why it matters
The new disclosure is quantitative PET imaging evidence (SUV and SUVR reductions) in the third MSA patient to complete dosing, supporting biological activity and justifying continued evaluation in additional patients.
Market read
Incremental Phase 2 biomarker readout in MSA can move trading expectations for TLSA, but it is not yet a clinical efficacy endpoint.
What to watch
The CEO quote emphasizes confidence, but the article does not provide safety updates, dosing details, or clinical outcome correlations, which are key for valuation progression.
Background
Tiziana is a clinical-stage biotech developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in Phase 2 for Multiple System Atrophy (MSA).
Ticker impact
Tiziana reports PET imaging reductions in inflammatory activity in a third MSA patient treated with intranasal foralumab, with up to 34% SUV and 26% SUVR declines.
Near-term upside bias versus prior expectations, but likely capped by small sample size and lack of clinical endpoint data.
The article discloses new quantitative imaging results from an additional patient (third to complete dosing), which is a tangible catalyst for a clinical-stage biotech, though it remains biomarker-level and early-stage.
Market effects
Reinforces the anti-CD3 intranasal mucosal tolerance approach as a neuroinflammation biomarker strategy in MSA, which may influence sentiment toward similar neuroimmunology programs.
Limited direct regional spillover; primarily impacts US small-cap biotech sentiment.
MSA is global, but the disclosure is company-specific and unlikely to move broader global biotech indices without larger trial readouts.
Counterpoint
PET biomarker reductions across three patients may not translate into meaningful clinical benefit, and the sample size is too small to de-risk efficacy.
Key entities
- companyTiziana Life Sciences, Ltd.
Nasdaq-listed biotech developing intranasal foralumab for neuroinflammatory neurodegenerative diseases.
- drug_candidateIntranasal foralumab
Fully human anti-CD3 monoclonal antibody designed to modulate immune response via mucosal tolerance.
- diseaseMultiple System Atrophy (MSA)
Rare, progressive neurodegenerative disorder with no approved disease-modifying treatments.
- biomarkerPET imaging (SUV, SUVR)
Quantitative imaging measures used to assess inflammatory activity in disease-relevant brain regions.
